JPRN-UMIN000016546已完成未知
Phase I clinical trial of JPH203 in patients with solid cancers. - JPH203-SBECD-PI
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient with severe disorders and/or unstable complications except cancers evaluated by investigator, and psychopathy impeding informed consent, study and subject safety 2) Patient with infection required systemic therapy 3) Patient with positive HIV-1 or HCV antibody, or HBs antigen 4) Patient with ECG abnormality 5) Patient with pleural fluids, pericardial effusions or ascites required drainage 6) Patient with brain metastasis or cancerous body fluid seen by imaging. 7) Patient receiving irradiation over 1/3 of hematopoietic bone 8) Patient with frequent diarrhea or watery stool 9) Pregnant or nursing pregnant patients disagreed with contraception 90 days after last receipt of study drug. 10) Patient with continuously systemic steroid therapy 11) Patient received cyto-reductive chemotherapy, irradiation and immune therapy within 4 weeks before the trial 12) Patient whom investigator evaluates unsuitable
研究者
相似试验
已完成
1 期
A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantatioStandard primary treatment-refractory acute GVHDJPRN-UMIN000001716JCR pharmaceuticals Co.,Ltd20
已完成
2 期
A Phase II/III trial of JR-031 for the treatment of steroid-refractory acute Graft-versus-Host disease after hematopoietic stem cell transplantioSteroid-refractory acute Graft-versus-Host diseaseJPRN-UMIN000006719JCR pharmaceuticals Co., Ltd.25
进行中（未招募）
1 期
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaRelapsed/Refractory B-cell Non-Hodgkin's LymphomaNCT05618327Shanghai Junshi Bioscience Co., Ltd.104
已完成
不适用
A phase III open clinical study of SJP-0118 in patients who schedule intraocular surgeryJPRN-UMIN000026494Senju Pharmaceutical Co.,Ltd.150
未知
1 期
Phase I/II clinical trial of inactivated HVJ-E administration for advanced malignant melanoma patientsJPRN-UMIN000002376Department of Dermatology Osaka University Graduate School of Medicine6